Browse FLT3LG

Summary
SymbolFLT3LG
Namefms-related tyrosine kinase 3 ligand
Aliases FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Secreted.
Domain PF02947 flt3 ligand
Function

Stimulates the proliferation of early hematopoietic cells by activating FLT3. Synergizes well with a number of other colony stimulating factors and interleukins.

> Gene Ontology
 
Biological Process GO:0000768 syncytium formation by plasma membrane fusion
GO:0001773 myeloid dendritic cell activation
GO:0001779 natural killer cell differentiation
GO:0001894 tissue homeostasis
GO:0002158 osteoclast proliferation
GO:0002274 myeloid leukocyte activation
GO:0002521 leukocyte differentiation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0006949 syncytium formation
GO:0007520 myoblast fusion
GO:0010830 regulation of myotube differentiation
GO:0010831 positive regulation of myotube differentiation
GO:0014902 myotube differentiation
GO:0030098 lymphocyte differentiation
GO:0030101 natural killer cell activation
GO:0030885 regulation of myeloid dendritic cell activation
GO:0032814 regulation of natural killer cell activation
GO:0032816 positive regulation of natural killer cell activation
GO:0032823 regulation of natural killer cell differentiation
GO:0032825 positive regulation of natural killer cell differentiation
GO:0035162 embryonic hemopoiesis
GO:0042692 muscle cell differentiation
GO:0045445 myoblast differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045661 regulation of myoblast differentiation
GO:0045663 positive regulation of myoblast differentiation
GO:0045787 positive regulation of cell cycle
GO:0048568 embryonic organ development
GO:0048871 multicellular organismal homeostasis
GO:0048872 homeostasis of number of cells
GO:0048873 homeostasis of number of cells within a tissue
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0051146 striated muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051149 positive regulation of muscle cell differentiation
GO:0051153 regulation of striated muscle cell differentiation
GO:0051155 positive regulation of striated muscle cell differentiation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0060142 regulation of syncytium formation by plasma membrane fusion
GO:0060143 positive regulation of syncytium formation by plasma membrane fusion
GO:0060249 anatomical structure homeostasis
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071838 cell proliferation in bone marrow
GO:0071839 apoptotic process in bone marrow
GO:0071863 regulation of cell proliferation in bone marrow
GO:0071864 positive regulation of cell proliferation in bone marrow
GO:0071865 regulation of apoptotic process in bone marrow
GO:0071866 negative regulation of apoptotic process in bone marrow
GO:0090289 regulation of osteoclast proliferation
GO:0090290 positive regulation of osteoclast proliferation
GO:1901739 regulation of myoblast fusion
GO:1901741 positive regulation of myoblast fusion
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
Molecular Function GO:0005125 cytokine activity
GO:0030971 receptor tyrosine kinase binding
GO:1990782 protein tyrosine kinase binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0031233 intrinsic component of external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04640 Hematopoietic cell lineage
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-449147: Signaling by Interleukins
Summary
SymbolFLT3LG
Namefms-related tyrosine kinase 3 ligand
Aliases FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FLT3LG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FLT3LG and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16651446SarcomaPromote immunity (infiltration)We have observed that the treatment of BALB/c mice bearing syngeneic CMS4 sarcomas with the combination of recombinant Flt3 ligand and recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) for five sequential days is sufficient to optimize the number of tumor-infiltrating dendritic cells (TIDC).
21505426GlioblastomaPromote immunityIn a model of GBM recurrence, we demonstrate that Flt3L/TK mediated immunological memory is capable of recognizing brain tumor neoantigens absent from the original treated tumor. These data demonstrate that the Flt3L/TK gene therapeutic approach can induce systemic immunological memory capable of recognizing a brain tumor neoantigen in a model of recurrent GBM.
Summary
SymbolFLT3LG
Namefms-related tyrosine kinase 3 ligand
Aliases FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FLT3LG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFLT3LG
Namefms-related tyrosine kinase 3 ligand
Aliases FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FLT3LG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1190.764
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2190.879
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.380.669
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5920.139
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.2320.353
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2190.891
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4720.33
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.3570.0702
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5620.502
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.9110.117
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6820.375
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.140.265
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FLT3LG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFLT3LG
Namefms-related tyrosine kinase 3 ligand
Aliases FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FLT3LG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFLT3LG
Namefms-related tyrosine kinase 3 ligand
Aliases FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FLT3LG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FLT3LG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFLT3LG
Namefms-related tyrosine kinase 3 ligand
Aliases FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FLT3LG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFLT3LG
Namefms-related tyrosine kinase 3 ligand
Aliases FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FLT3LG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFLT3LG
Namefms-related tyrosine kinase 3 ligand
Aliases FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FLT3LG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFLT3LG
Namefms-related tyrosine kinase 3 ligand
Aliases FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FLT3LG collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.